country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-P992540

Copy Link Print Information

IBI389

IBI389 is an anti-Claudin18.2 × CD3 bispecific antibody. IBI389 binds CD3 and Claudin18.2 to engage T cells, induce immune synapse formation, and redirect T cell killing of Claudin18.2-positive tumors. IBI389 increases intratumoral CD3⁺/CD8⁺ T cells, an immuno-inflammatory phenotype, shortens tumor-T cell distance, compensatorily increases regulatory T cells, and elevates IL-2/IFN-γ; IL-4/IL-10/IL-17A/TNF-α are decreased. IBI389 can be used in gastric cancer-related research.

For research use only. We do not sell to patients.

Storage:

Please store the product under the recommended conditions in the Certificate of Analysis.

IBI389 Chemical Structure

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Use of MCE Products

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- Species Reactivity
- IC₅₀ & Target
- In Vivo
- Target
- Conjugated
- Application
Chemical Information
Purity & Documentation
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

Description

Species Reactivity

Human

IC₅₀ & Target

^[1]

IL-10

IL-17A

IL-4

IL-2

TNF-α

All Interleukin Related Isoforms :

All TNF Receptor Isoforms :

In Vivo

IBI389 (1-10 mg/kg; i.v.; every 2 weeks) suppresses tumor growth and increases intratumoral CD3⁺ T-cell infiltration in the AGS gastric cancer xenograft, with the greatest tumor control and immune infiltration when combined with PD-1 blockade^[1].
IBI389 (1-10 mg/kg; i.v.; every 2 weeks) suppresses tumor growth and increases intratumoral CD3⁺ T-cell density in the KPC pancreatic cancer model, and combination with PD-1 blockade provides the strongest tumor inhibition^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Related Protocols :

Research Protocol for Cancer Immunology

Target

Claudin18.2 & CD3

Conjugated

Unconjugated

Application

ELISA, FACS, Functional assay

Chemical Information

SMILES

[IBI389]
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Inhibitory Antibodies User Guide (603 KB)

References

[1]. Zhu Y, et al. The claudin-18.2-CD3 bispecific antibody IBI389 exerts an antitumor effect on malignant tumors with positive claudin-18.2 expression by promoting T-cell infiltration and remodeling the tumor immune microenvironment. Translational Cancer Research. 2026;15(3).

[2]. Li X, et al. Safety and preliminary efficacy results of IBI389, an anti-Claudin18.2×CD3 bispecific antibody, in patients with solid tumors and gastric or gastro-esophageal tumors: a phase 1 dose escalation and expansion study. BMC medicine. 2026 Jan 16;24(1):91.

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

Get Quote In-stock

Other size

Get Quote